Background {#Sec1}
==========

Bloodstream infection (BSI) contributes substantially to morbidity and mortality worldwide \[[@CR1]\]. In Europe, the annual number of BSI episodes and deaths associated with BSI has been estimated to 1.2 million and 157,000, respectively \[[@CR1]\]. Early diagnosis and early appropriate treatment is crucial. In severe sepsis, the case fatality increases for each hour the antibiotic treatment is delayed \[[@CR2], [@CR3]\]. Therefore, empirical antibiotic treatment has to be initiated before the results of blood cultures are available. However, as infections with resistant microbes is an escalating problem worldwide \[[@CR4]--[@CR6]\], it is increasingly challenging to maintain appropriate antibiotic regimens for initial empiric therapy. Resistant pathogenic bacteria are found less frequently in Norway and other Nordic countries, compared to the rest of Europe and other world regions \[[@CR7], [@CR8]\]. This probably reflects a relatively restrictive use of antimicrobial agents. In Norway, a regimen containing penicillin and gentamicin (PG), plus metronidazole (PGM) if an anaerobic infection is suspected, has been recommended for more than thirty years in sepsis with unknown focus and etiology \[[@CR9]--[@CR11]\]. In recent years, however, increasing numbers of infections with methicillin-resistant *Staphylococcus aureus* (MRSA), extended-spectrum beta-lactamase producing *Enterobacteriaceae* (ESBL-E), and vancomycin resistant enterococci have been detected \[[@CR8]\]. Selection of inherently resistant microbes due to antibiotic use is also a challenge. Updated knowledge about the distribution of microbes in serious infections and their resistance against antimicrobial agents is needed to ensure appropriate empiric antimicrobial treatment regimens. It is also important to identify subgroups in which tailored regimens are required. Important differences in antibiotic resistance have been found with regard to place of acquisition \[[@CR12], [@CR13]\], and therefore, resistance statistics should specify results for community acquired (CA), health care-associated (HCA), and hospital acquired (HA) infections.

We conducted a prospective study to assess the occurrence and distribution of BSI microbes and their non-susceptibility to some common antibiotic regimens for initial empiric antimicrobial treatment of sepsis of unknown etiology. Particularly, we assessed microbes and antimicrobial resistance by place of acquisition (CA, HCA and HA-BSIs) and with regard to time trends over a 12-year period. We also studied the antibiotic regimens that were used for initial empiric treatment during the same time period and the degree to which they were appropriate.

Methods {#Sec2}
=======

Levanger Hospital serves a population of about 90,000 as an emergency facility in a defined geographical area of Mid-Norway. Since 1994, all positive blood cultures at the hospital have been prospectively recorded for surveillance purposes, and clinical information has been recorded, in the following way: whenever a positive blood culture was reported, a physician at the clinical ward filled out a registration form. A team of three research nurses, two subordinate doctors, and the main investigator reviewed all patients' records to verify the data and record additional variables. The present study includes BSIs that occurred between January 1, 2002 and December 31, 2013 in patients who were ≥16 years of age, and it is part of the Mid-Norway Sepsis Study.

The microbiology laboratory at Levanger Hospital is ISO 15189 accredited and participates in the national quality assurance schemes (ring tests). Blood cultures were performed in BACTEC 9240 Vacutainer Culture Bottles (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD) \[[@CR14]\], which in 2010 was replaced by BACTEC FX. No obvious changes in blood culture techniques or indications for drawing blood cultures have been done during the study period, but an increased focus on early detection of sepsis may have influenced the rate of blood culture sampling. Over the study period, the number of blood culture sets per 1000 hospital bed-days increased from 25.0 in 2002 to 59.5 in 2013.

Isolates were identified using standard methods \[[@CR15]\]. Antimicrobial susceptibility testing was performed by the disc diffusion method (Neo-Sensitabs, Rosco Diagnostica, Taastrup, Denmark). For measurement of MIC, E-test (AB Biodisk, Solna, Sweden) was used. The results of antibacterial susceptibility testing were interpreted according to the Norwegian Working Group on Antibiotics (NWGA). For the antibiotics included in this study, the Norwegian breakpoints correspond to EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints \[[@CR8], [@CR16]\]. In this study, microbes intermediately susceptible to antibiotics were classified as non-susceptible \[[@CR17]--[@CR19]\], as only susceptible microbes can be regarded as being able to be managed by means of the respective antibiotic regimens. Microbes not tested in the laboratory because of known inherent non-susceptibility (e.g. enterococci are inherently resistant to cephalosporins) were classified as non-susceptible (see Additional file [1](#MOESM1){ref-type="media"}: Appendix 1 On inherent (natural) resistance in microbes).

An episode of BSI was defined by growth of one or more microbes from blood culture combined with clinical evidence of systemic infection. A new BSI episode with the same microbe in the same patient was recorded if an interval of at least 30 days had passed without signs of infection since an earlier episode \[[@CR20]\]. If more than one organism was isolated from one or more blood cultures within a 72-h period, the BSI episode was classified as polymicrobial. One positive blood culture for organisms usually regarded as etiological agents was the requirement for inclusion. For coagulase-negative staphylococci or other possible skin contaminants, at least two identical isolates from separate venipunctures were required. Among alpha-hemolytic streptococci, *S. pneumoniae* and streptococci belonging to the *S. milleri* group were not considered as skin contaminants. Other alpha-hemolytic streptococci were included if they were found in two or more blood cultures from different venipuncture sites.

The place of acquisition was classified as hospital-acquired (HA), health care-associated (HCA) or community acquired (CA) \[[@CR12], [@CR21]\]. HA-BSI was diagnosed if the infection was detected \>48 h after admission \[[@CR22]\]. Patients who during the 30 days prior to hospital admission had (1) been hospitalized two or more days or (2) had received intravenous therapy or wound care at home or (3) hemodialysis or chemotherapy at hospital visits or (4) were nursing home residents, were categorized as having HCA-BSI. CA-BSI was diagnosed if the infection was detected \<48 h after admission and none of the criteria for HCA-BSI were fulfilled.

A urinary focus was assigned when there was growth of the same microbe (s) from urine as well as from blood culture along with clinical signs/symptoms or risk factor for urinary infection, and no other source of infection was identified. A presumed pulmonary focus was diagnosed with clinical signs of lower respiratory infection accompanied by positive radiological findings. Focus in the biliary tract was ascertained based on clinical, biochemical and radiological findings. Signs of infection along with focal growth of the same microbe as in blood culture were taken as a confirmation of infection in abdomen, skin, soft tissue or other sites. An unknown focus of infection was assigned when none of the criteria for ascertaining a focus were met.

Appropriate empiric antibiotic therapy (AEAT) was defined as correctly dosed intravenous antibiotic therapy with a regimen that was active in vitro against the microbe(s) isolated from blood culture (s). We assessed AEAT within 6 h and within 24 h of the time that the blood culture specimen was obtained.

Statistical analyses {#Sec3}
--------------------

Proportions of non-susceptibility across place of acquisition categories and time periods were assessed by a two-sided chi-square test. Trends in proportions were analyzed using Cochran-Armitage test. Two-sided p-values \<0.05 were considered significant. Confidence intervals were calculated using Wilson's approximation to the binominal distribution \[[@CR23]\]. The analyses were performed using SPSS 22, STATA 13, and StatXact 9.

Results {#Sec4}
=======

During the 12-year study period, a total of 1995 episodes of BSI occurred among 1719 individuals. CA-BSI episodes amounted to 46.8% of the total, HCA- and HA-BSI contributed 39.4% and 13.7%, respectively (Table [1](#Tab1){ref-type="table"}). *Escherichia coli* was the predominating microbe (34.4%), followed by *Streptococcus pneumoniae* (11.3%) and *Staphylococcus aureus* (10.9%). The distribution of microbes by place of acquisition is shown in Fig. [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1. The distribution of microbes by infection site is shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2. Totally, the number of BSIs increased across the three 4-year periods 2002--2005, 2006--2009, and 2010--2013 (Table [1](#Tab1){ref-type="table"}). Most microbes contributed essentially similar proportions of the BSIs in each of the three time periods. However, the proportions of BSI from *Klebsiella* spp. (3.8% vs. 8.9%) and *Candida* spp. (0.3% vs. 1.3%) increased from the first to the third period. Conversely, the proportion of BSI from *Streptococcus pneumoniae* decreased from 13.8 to 8.4%.Table 1Bloodstream infection (BSI) episodes in three time periodsTotal2002--20052006--20092010--2013All BSIs1995 (100,0)582 (100.0)638 (100.0)775 (100.0)Place of acquisition Community acquired934 (46.8)317 (54.5)280 (43.9)337 (43.5) Health care-associated787 (39.4)175 (30.1)277 (43.4)335 (43.2) Hospital acquired274 (13.7)90 (15.5)81 (12.7)103 (13.3)Microbial agent(s)  *Escherichia coli*686 (34.4)186 (32.0)231 (36.2)269 (34.7)  *Streptococcus pneumoniae*225 (11.3)80 (13.8)80 (12.5)65 (8.4)  *Staphylococcus aureus*218 (10.9)72 (12.4)55 (8.6)91 (11.7)  *Klebsiella* spp.135 (6.8)22 (3.8)44 (6.9)69 (8.9) Beta-hemolytic streptococci104 (5.2)33 (5.7)35 (5.5)36 (4.6)  *Enterococcus* spp.89 (4.5)28 (4.8)26 (4.1)35 (4.5) Other mixed bacterial infections68 (3.4)21 (3.6)19 (3.0)28 (3.6)  *Pseudomonas* spp.58 (2.9)20 (3.4)21 (3.3)17 (2.2) Viridans group streptococci57 (2.9)15 (2.6)19 (3.0)23 (3.0) Coagulase-negative staphylococci54 (2.7)23 (4.0)11 (1.7)20 (2.6)  *Proteus* spp.48 (2.4)17 (2.9)15 (2.3)16 (2.1) Anaerobic Gram-negative bacteria45 (2.3)14 (2.4)16 (2.5)15 (1.9) Mixed Gram-negative aerobic or anaerobic bacteria42 (2.1)13 (2.2)11 (1.7)18 (2.3) Enterobacter spp.37 (1.9)8 (1.4)14 (2.2)15 (1.9) Other *Enterobacteriaceae*37 (1.9)7 (1.2)12 (1.9)18 (2.3) Other aerobic Gram-negative bacteria19 (1.0)5 (0.9)4 (0.6)10 (1.3)  *Haemophilus influenzae*17 (0.9)6 (1.0)8 (1.3)3 (0.4)  *Candida* spp.14 (0.7)1 (0.2)4 (0.6)9 (1.3) Anaerobic Gram-positive bacteria11 (0.6)3 (0.5)4 (0.6)4 (0.5) Mixed gram-positive aerobic or anaerobic bacteria11 (0.6)1 (0.2)4 (0.6)6 (0.8)  *Neisseria meningitidis*9 (0.5)4 (0.7)2 (0.3)3 (0.4)  *Listeria monocytogenes*8 (0.4)2 (0.3)2 (0.3)4 (0.5) Mixed bacterial and fungal infections3 (0.2)1 (0.2)1 (0.2)1 (0.1)The table shows number (percent) of BSIs overall, by place of acquisition, and by microbial agent(s) Fig. 1Distribution of microbes from 1995 bloodstream infection episodes by place of acquisition. (Additional file [1](#MOESM1){ref-type="media"}: Table S1 shows microbial agents by place of acquisition in more detail)

In vitro susceptibility to antibiotics {#Sec5}
--------------------------------------

Overall, 6.1% of the microbes were non-susceptible to a regimen consisting of penicillin and gentamicin (PG), and 3.5% were non-susceptible to a triple agent regimen including penicillin, gentamicin, and metronidazole (PGM) (Table [2](#Tab2){ref-type="table"}). The proportions not susceptible to imipenem, piperacillin-tazobactam (PIP/TAZ), and cefotaxime, were 4.5%, 7.6%, and 17.8%, respectively. A broad-spectrum combination containing PIP/TAZ, gentamicin, and metronidazole had the lowest degree of non-susceptibility (2.6%), whereas ceftazidime had the highest (27.8%) (Table [2](#Tab2){ref-type="table"}).Table 2The proportion (%) of bloodstream infection (BSI) episodes with microbe(s) non-susceptible to some common antibiotic regimensTotal2002--2005^a^2006--20092010--2013p for trendPenicillin-gentamicin Total6.14.46.17.50.011 Community acquired4.32.25.75.00.22 Health care-associated6.77.45.87.20.16 Hospital acquired10.24.48.616.50.023 p for trend0.0060.0580.460.003Penicillin-gentamicin-metronidazole Total3.51.93.05.2\<0.001 Community acquired1.40.31.82.10.28 Health care-associated4.84.63.26.30.045 Hospital acquired6.92.26.211.70.026 p for trend\<0.0010.0070.150.001Piperacillin/tazobactam Total (*n* = 1413)7.67.47.70.25 Community acquired (*n* = 617)3.62.94.20.27 Health care-associated (*n* = 612)8.89.48.40.31 Hospital acquired (*n* = 184)8.89.417.00.31 p for trend\<0.001\<0.001\<0.001Piperacillin/tazobactam-gentamicin Total (*n* = 1413)3.02.43.60.21 Community acquired (*n* = 617)1.00.71.20.69 Health care-associated (*n* = 612)3.33.23.30.98 Hospital acquired (*n* = 184)9.24.912.60.12 p for trend\<0.0010.037\<0.001Piperacillin/tazobactam-gentamicin-metronidazole Total (*n* = 1413)2.61.73.40.065 Community acquired (*n* = 617)0.50.00.90.26 Health care-associated (*n* = 612)2.92.53.30.64 Hospital acquired (*n* = 184)8.74.911.70.12 p for trend\<0.0010.004\<0.001Imipenem Community acquired1.11.60.70.90.59 Health care-associated6.59.15.85.70.39 Hospital acquired10.611.17.412.60.14 p for trend\<0.001\<0.0010.001\<0.001Cefotaxime Total17.817.518.717.30.68 Community acquired10.811.011.410.10.69 Health care-associated21.325.122.718.20.18 Hospital acquired31.425.629.637.90.31 p for trend\<0.001\<0.001\<0.001\<0.001Ceftazidime Total27.829.024.829.40.25 Community acquired18.520.215.419.60.42 Health care-associated31.336.028.231.30.37 Hospital acquired49.646.745.755.30.46 p for trend\<0.001\<0.001\<0.001\<0.001^a^Piperacillin/tazobactam was not adopted in the first time periodThe BSIs are stratified by place of acquisition and by time period (the total number in each cell is shown under the heading Place of acquisition in Table [1](#Tab1){ref-type="table"})

The non-susceptibility to PGM was higher in HA-BSI (6.9%) and HCA-BSI (4.8%) than in CA-BSI (1.4%) (*p* \< 0.001). Similar differences across place of acquisition were seen for imipenem, PIP/TAZ, and cefotaxime (Fig. [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Table S3). The proportions of microbes non-susceptible to PGM increased through the three time periods in HA-BSI (2.2%, 6.2%, and 11.7%; *p* = 0.026), but we observed no significant time trends in antibiotic susceptibility for other antibiotic regimens (Table [2](#Tab2){ref-type="table"}). Proportions of non-susceptibility by microbe are shown in Table [3](#Tab3){ref-type="table"}. Non-susceptibility by site of infection is shown in Additional file [1](#MOESM1){ref-type="media"}: Table S4.Fig. 2Proportion of bloodstream infection microbes non-susceptible to four antibiotic regimens by place of acquisition Table 3Proportions (%) of different microbes or microbe groups non-susceptible to some commonly recommended antibiotics and antibiotic regimensMicrobe/microbe groupAntibiotics and antibiotic combinations (2002--2013)P/T alone or in combinations (2006--2013)PGPGMImi-penemCefo-taximeCefta-zidimeCipro-floxa-cinTotal NP/TP/T-GP/T-G-MTotal N*Streptococcus pneumoniae*§0.90.90.00.40.4NRT2260.70.70.7146Beta-hemolytic streptococci0.00.00.00.0100.0NRT1040.00.00.071Viridans streptococci0.00.00.03.58.8NRT570.00.00.042*Staphylococcus aureus*\#0.50.50.00.0100.0 (IR)NRT2180.00.00.0146Coagulase-negative staphylococci13.013.038.938.9100.0 (IR)NRT5441.919.419.431*Enterococcus* spp.9.09.011.2100.0 (IR)100.0 (IR)NRT8911.59.89.861*Listeria monocytogenes*0.00.00.0100.0 (IR)100.0 (IR)NRT80.00.00.06*Escherichia coli*1.91.90.11.91.93.36866.00.80.8500*Klebsiella* spp. or *Proteus* spp.0.00.05.52.22.24.71827.00.00.0143Other enterobacteria1.41.49.520.321.62.97416.9100.0100.059*Pseudomonas* spp.1.71.76.9100.0\
(IR)3.48.2585.32.62.638Other aerobic Gram-negatives8.98.98.931.128.96.74523.30.00.030Anaerobic bacteria66.13.60.096.496.4NRT565.17.70.039Mixed bacterial infection24.811.613.248.850.4NRT12111.68.14.786*Candida* spp. single or in mixed infection100.0 (IR)100.0 (IR)100.0 (IR)100.0 (IR)100.0 (IR)100.0 (IR)17100.0 (IR)100.0 (IR)100.0 (IR)15Total6.13.54.517.827.8NRT19957.63.02.61413§two isolates of penicillin-non-susceptible pneumococci were detected\#one single isolate of methicillin-resistant *Staphylococcus aureus* (MRSA) and one single isolate of gentamicin-resistant *S. aureus* were detectedIR, inherently resistant (see Additional file [1](#MOESM1){ref-type="media"}: Appendix 1 On inherent (natural) resistance in microbes); NRT, not routinely tested; PG, penicillin-gentamicin; PGM, penicillin-gentamicin-metronidazole; P/T, piperacillin-tazobactam; P/T-G, piperacillin-tazobactam plus gentamicin; P/T-G-M, piperacillin-tazobactam plus gentamicin plus metronidazolePiperacillin-tazobactam (P/T) was adopted in 2006

Among seventy BSI episodes with microbes non-susceptible to PGM (Fig. [3](#Fig3){ref-type="fig"}; Additional file [1](#MOESM1){ref-type="media"}: Table S5), *Candida* spp. accounted for 17 episodes, *E. coli* 16, and *Enterococcus faecium* and *Staphylococcus epidermidis* for 9 episodes each. The great majority of episodes with *Candida* spp., *Enterococcus faecium* or *Staphylococcus epidermidis* occurred in HCA or HA-BSI, and the highest numbers were recorded in the third time period. Regarding *E. coli* not susceptible to PGM (which means not susceptible to gentamicin), seven episodes occurred in CA, eight in HCA, and one in HA-BSI. The number of *E. coli* isolates non-susceptible to gentamicin was one (0.5%) in 2002--2005, six (2.6%) in 2006--2009, and nine (3.3%) in 2010--2013 (Additional file [1](#MOESM1){ref-type="media"}: Table S6).Fig. 3Microbes non-susceptible to penicillin-gentamicin-metronidazole (PGM) through three time periods. (Additional file [1](#MOESM1){ref-type="media"}: Table S5 shows the PGM non-susceptible microbes in detail) ANS, acquired non-susceptibility; INS, inherent non-susceptibilty

The proportions of *E. coli* producing extended-spectrum beta-lactamase (ESBL) were 0% in 2002--05, 2.0% in 2006--09, and 1.7% in 2010--13 (Additional file [1](#MOESM1){ref-type="media"}: Table S7). Only one episode of methicillin-resistant *Staphylococcus aureus* (MRSA) was found, and only in two (0.9%) of 225 BSIs with *Streptococcus pneumoniae*, the microbe was non-susceptible to penicillin (Additional file [1](#MOESM1){ref-type="media"}: Table S3).

Initial empiric antibiotic therapy {#Sec6}
----------------------------------

The use of second- and third generation cephalosporins as initial empiric therapy decreased through the study periods. Cefuroxime was used as monotherapy or in combination in 19.6% and 5.3% of the BSI episodes in the first and in the third time period, respectively. The corresponding proportions for cefotaxime were 18.1% and 15.7% (Table [4](#Tab4){ref-type="table"}). In contrast, the use of ampicillin or penicillin plus gentamicin increased from 14.1% to 19.9%. PIP/TAZ was not used in the first period, but was the second most used empiric therapy in the third period (17.3%). The proportions of patients who received appropriate empiric antibiotic therapy (AEAT) within 6 h and within 24 h were larger in the third period than in the first and second periods (Table [5](#Tab5){ref-type="table"}). The proportions of patients who received AEAT within 6 h in the third period were 67.1% in CA, 67.2% in HCA, and 59.0% in HA-BSI. The corresponding proportions who received AEAT within 24 h were 88.4%, 84.4%, and 83.1%, respectively.Table 4The most commonly used initial empiric antibiotic regimens (percent) through three time periodsInitial antibiotic regimen2002--2005 (*n* = 582)2006--2009 (*n* = 638)2010--2013 (*n* = 775)Cefotaxime18.118.215.7Penicillin/ampicillin-gentamicin14.114.619.9Penicillin14.114.38.1Piperacillin-tazobactam08.617.3Cefuroxime-metronidazole9.88.14.1Cefotaxime-metronidazole3.65.65.5Mecillinam5.04.74.9Cefuroxime9.83.41.2Penicillin-gentamicin-metronidazole5.93.41.7A complete table showing initial treatment in 1995 bloodstream infection episodes is found in Additional file [1](#MOESM1){ref-type="media"}: Table S8 Table 5Appropriate empiric antibiotic therapy (AEAT) through three time periods by place of acquisition2002--2005 (*n* = 582)2006--2009 (*n* = 638)2010--2013 (*n* = 775)AEAT within 6 h Community acquired BSI61.763.467.1 Health care-associated BSI64.053.667.2 Hospital acquired BSI43.946.459.0AEAT within 24 h Community acquired BSI84.289.488.4 Health care-associated BSI76.781.384.4 Hospital acquired BSI72.273.983.1Percent of patients with bloodstream infection (BSI) receiving AEAT within 6 h and within 24 h

Discussion {#Sec7}
==========

In this prospective study of 1995 consecutive BSIs at a medium-sized Norwegian hospital between 2002 and 2013, antimicrobial resistance was a far smaller problem than reported in most studies \[[@CR7], [@CR17], [@CR24], [@CR25]\]. Except for third-generation cephalosporins, antimicrobial resistance to regimens recommended for sepsis of unknown etiology was low. In less than 4% of BSI episodes, microbes were non-susceptible to PGM, consistent with previous findings at our hospital \[[@CR26]\] and in other Norwegian studies \[[@CR10], [@CR27]\]. However, the proportion of antibiotic non-susceptibility was higher in HA and HCA than in CA-BSI. For PGM, an increase in non-susceptibility through the study period was observed in HA-BSI, mainly caused by inherently resistant microbes. A slightly increasing number of bacteria with acquired resistance was also detected, particularly *E. coli* producing ESBL or possessing gentamicin resistance. In our cohort, appropriate empiric antibiotic therapy could be achieved to a larger extent by replacing cephalosporins with PG or PIP/TAZ.

Strengths of this study include the prospective registration of BSIs within a well-defined area, and the handling of blood cultures at one microbiology laboratory. We present susceptibility data by microbe, by place of acquisition, and by site of infection. Most authors have presented susceptibility data only by microbe, which is generally unknown at the time the physician has to decide on the initial antimicrobial therapy. We included microbes with known inherent resistance in the presentation in order to give guidance for empirical treatment before the microbial etiology is known. Our use of one single institution as the study site limits the generalizability of our results, but regarding antibiotic resistance patterns as basis for treatment guidelines, our results may be relevant for other general hospitals in Scandinavia.

The low proportions of non-susceptibility in our BSI microbes are likely explained by a relatively strict use of antibiotics in Norway \[[@CR8], [@CR28], [@CR29]\]. All antibiotics used in humans are prescribed by physicians, and penicillins and aminoglycosides are the preferred drugs in severe bacterial infections. The increasing non-susceptibility in BSI microbes by place of acquisition and, for HA-BSI, by time period, was mainly due to a shift towards microbes with natural (inherent) resistance, particularly *Candida* spp., *Enterococcus faecium*, and *Staphylococcus epidermidis*. We attribute this shift to the increasing use of chemotherapy and other immunosuppressive treatments (Additional file [1](#MOESM1){ref-type="media"}, Table S9), which results in more prevalent infections and antibiotic treatments, giving rise to selection of resistant microbes. A higher proportion of non-susceptible microbes in HA and HCA than in CA-BSI is well known from other studies \[[@CR12], [@CR13]\], but this cautionary knowledge does not seem to have been sufficiently heeded by clinicians and guideline makers. The national Norwegian surveillance data on the distribution of different microbes isolated from blood cultures show no time trend towards increasing occurrence of natural resistant microbes from 2004 to 2014 \[[@CR8], [@CR30]\], but do not distinguish between CA, HCA, and HA infection. The European Antimicrobial Resistance Surveillance Network (EARS-Net) reported increasing occurrence of *Enterococcus faecium* from 2002 to 2008 \[[@CR7]\], but *Candida* spp. and *S. epidermidis* are not included in the EARS-Net surveillance.

Acquired resistance was uncommon in our BSI cohort, but an increasing proportion of *E. coli* was non-susceptible to gentamicin, and they occurred in CA as well as in HCA-BSIs. Nationwide, a worrying increase in resistance to gentamicin has emerged from 2003 to 2014 (0.6% to 7.7%) \[[@CR8]\]. The EARS-Net has reported 5.2% and 9.9% aminoglycoside resistance in *E. coli* in 2002 and 2013, respectively \[[@CR7], [@CR24]\], but the proportion of aminoglycoside resistance was much higher in the south-eastern region (32.1% in Bulgaria in 2013). The proportion of *E. coli* producing ESBL has increased from 2008 to 2014 (1.5% to 5.8%) according to the national data \[[@CR8]\], and according to EARS-Net data, the proportion of ESBL-producing *E. coli* in Europe increased from 2.0% in 2002 \[[@CR24]\] to 12.6% in 2013 (39.6% in Bulgaria) \[[@CR7]\].

One single isolate of MRSA and two pneumococci intermediately susceptible to penicillin were found in our cohort. Nationwide, the proportion of MRSA in blood cultures has been low in the corresponding time period (0.3% and 0.8% in 2002 and 2014, respectively). The low occurrence of MRSA in the Nordic countries and in the Netherlands clearly distinguishes from the other European countries, where MRSA accounted for \>25% of the *S. aureus* BSIs in 2007 \[[@CR25]\] but had decreased to 18% in 2013 \[[@CR7]\]. The nationwide proportion of invasive pneumococci non-susceptible to penicillin was 0.9% in 2002 and 5.5% in 2014 \[[@CR8], [@CR30]\]. In Europe, the proportion of penicillin-non-susceptible isolates in 2013 ranged from 1.1% (the Netherlands) to 40.0% (Cyprus) \[[@CR7]\]. Comparisons of trends in acquired non-susceptibility in the current study and in surveillance data from Norway and other European countries are shown in Table [6](#Tab6){ref-type="table"}.Table 6Comparisons of trends in acquired non-susceptibility in *Escherichia coli*, *Staphylococcus aureus*, and *Streptococcus pneumoniae*MicrobeType of non-susceptibilitySurveillance AreaTrends in proportions of non-susceptibility (Time period)*E. coli*Gentamicin non-susceptibilityLevanger Hospital0.5% (2002--05)3.3% (2010--13)Iceland2.9% (2010)4.1% (2013)Norway0.6% (2003)7.7% (2014)EU/EEA5.2% (2002)9.9% (2013)Bulgaria15.8% (2003)32.1% (2013)*E. coli*Resistance to 3rd generation cephalosporinsLevanger Hospital0 (2002--05)1.7% (2010--13)Norway1.5% (2008)5.8% (2014)EU/EEA2.0% (2002)12.6% (2013)Bulgaria24.8% (2010)39.6% (2013)*S. aureus*MRSALevanger Hospital0 (2002--05)1.0% (2010--13)Norway0.3% (2002)0.8% (2014)EU/EEA25.6% (2007)18.0% (2013)Malta52.0% (2007)51.8% (2013)Romania39.1% (2010)64.5% (2013)*S. pneumoniae*PNSPLevanger Hospital0 (2002--05)3.0% (2010--13)Netherlands2.0% (2010)1.1% (2013)Norway0.9% (2002)5.5% (2014)Cyprus41.7% (2010)40.0% (2013)MRSA, meticillin-resistant *Staphylococcus aureus*; PNSP, penicillin non-susceptible pneumococciProportions of non-susceptibility from the current study (Levanger Hospital) are compared with data from Norway (the national surveillance system \[[@CR8], [@CR30]\], the European Union/the European Economic Area (EU/EEA), and with countries which have extraordinary low or high proportions of non-susceptibility \[[@CR7], [@CR24], [@CR25]\]

Empirical antibiotic treatment regimens have to be continuously evaluated in accordance with national and local microbe resistance patterns. The initial empiric treatment for sepsis of unknown origin recommended by the National Professional Guidelines for Use of Antibiotics in Hospitals in Norway consists of penicillin and gentamicin, plus metronidazole (PGM) if an anaerobic infection is suspected \[[@CR11]\]. PGM was not effective in vitro against 3.5% of the microbes isolated from blood cultures in the present study. In patients with HA-BSI, however, the proportion of microbes not susceptible to PGM was 11.7% in the third time period. In defined subgroups we have to be aware of PGM resistant microbes and include vancomycin (e.g., suspected central venous catheter infection) or an antifungal drug (if suspected candida infection, e.g., long lasting broad-spectrum antibiotic therapy, long time stay in a ICU, particularly after gastrointestinal surgery), in our recommendations. Use of carbapenems in empiric therapy should be restricted to patients infected with bacteria resistant (known or suspected) to PIP/TAZ and in whom aminoglycoside therapy is contraindicated.

Enterococci are inherently resistant to cephalosporins and staphylococci are not susceptible to ceftazidime. In our BSI cohort, staphylococci and enterococci contributed to 30% of HA-BSI episodes. Noteworthy, the percentages of microbes non-susceptible to cefotaxime and ceftazidime in HA-BSI in the third period were as high as 37.9 and 55.3%, respectively. Therefore, none of these appears suitable for use as monotherapy in sepsis of unknown microbial origin. The emergence of ESBL in Gram-negative bacteria has made it even more risky to choose a third-generation cephalosporin as monotherapy for severe infections with unknown etiology.

Even though the National Professional Guidelines \[[@CR11]\] recommend PG (or PGM) as the regimen of first choice in sepsis of unknown etiology, the PG (or PGM) combination was given in no more than 20% of the episodes in our BSI cohort, yet the proportion was increasing with time. There are mainly two reasons for prescribing antibiotic treatment that does not include an aminoglycoside: (1) Aminoglycosides are potentially nephrotoxic and ototoxic. Therefore, there is a tendency to avoid them even in cases where they should not be contraindicated. (2) Use of an aminoglycoside requires measurement of aminoglycoside serum concentrations, which is resource consuming, and knowledge and experience is needed for assessment of the results. In a busy day, it is much simpler to administer a beta-lactam-antibiotic, where dosing is simple and the risk of toxicity is negligible.

In Norway, we lack national data for antibacterial treatment given in cases of bloodstream infection or sepsis. Regarding antibiotic use in Norwegian hospitals, the national surveillance data \[[@CR8]\] show that the proportion of aminoglycoside use was less than 5% in 2015 (3.3 out of 73 DDD/100 bed-days), indicating that avoiding aminoglycosides in favor of beta-lactam antibiotics is a common mode of acting countrywide.

The drawback of avoiding aminoglycosides is increased risk of antimicrobial resistance, as particularly cephalosporins are far more resistance driving than aminoglycosides. Therefore, a further shift in favor of aminoglycosides is desirable. As the use of aminoglycosides in our hospital and nationwide is still relatively low, overuse of aminoglycosides is unlikely to explain the observed increase in non-susceptibility to gentamicin in *E. coli*.

During the three time periods, we observed that the use of second- and third- generation cephalosporins decreased, whereas ampicillin or penicillin plus gentamicin were more frequently given. PIP/TAZ was introduced at our hospital in 2006, and the use of it has been increasing, particularly in the third period. Nationwide, the use of aminoglycosides and particularly piperacillin/tazobactam has increased during the last ten years, whereas the use of second-generation cephalosporins has decreased. The use of third-generation cephalosporins and fluoroquinolones peaked in 2011--2012 and have since then declined \[[@CR8]\]. These changes are in accordance with the national \[[@CR11]\] and local antibiotic policy, in order to achieve regimens that are less resistance driving and also cover the BSI microbes to a larger extent.

Conclusions {#Sec8}
===========

Antimicrobial resistance was a far smaller problem in our BSI cohort than is reported from countries outside Scandinavia. The antibiotic regimen recommended by Norwegian Health Authorities \[[@CR11]\], consisting of penicillin and gentamicin, and with metronidazole added when an anaerobic infection is suspected, is so far effective in vitro against a great majority of microbes isolated from BSI patients in this region. In our cohort, appropriate empiric antibiotic therapy was achieved to a larger extent by replacing second- and third-generation cephalosporins with penicillins and gentamicin. We must, however, be aware of an increasing occurrence of inherently resistant microbes, particularly in HA infection. There are also indications of increasing numbers of bacteria with acquired resistance, particularly *E. coli* producing ESBL and/or possessing gentamicin resistance, and these occurred predominantly in CA and HCA infections.
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AEAT

:   Appropriate empiric antibiotic therapy

BSI

:   Bloodstream infection

CA

:   Community acquired

EARS-Net

:   The European Antimicrobial Resistance Surveillance Network

ESBL

:   Extended-spectrum beta-lactamase

ESBL-E

:   Extended-spectrum beta-lactamase producing *Enterobacteriaceae*

EUCAST

:   European Committee on Antimicrobial Susceptibility Testing

HA

:   Hospital acquired

HCA

:   Health care-associated

NWGA

:   Norwegian Working Group on Antibiotics

PG

:   Penicillin plus gentamicin

PGM

:   Penicillin, gentamicin, and metronidazole

PIP/TAZ

:   Piperacillin-tazobactam
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